Effect of Guibi-Tang, a Traditional Herbal Formula, on Retinal Neovascularization in a Mouse Model of Proliferative Retinopathy

International Journal of Molecular Sciences

Yun Mi Lee²  Yu-Ri Lee²  Chan-Sik Kim²  Kyuhyung Jo²  Eunjin Sohn²  Jin Sook Kim²  Junghyun Kim¹ 

[1] KM Convergence Research Division, Korea Institute of Oriental Medicine, Daejeon 34054, Korea

关键词: retinal neovascularization;    fibroblast growth factor 2;    plasminogen activator inhibitor 1;    vascular endothelial growth factor;    oxygen-induced retinopathy;   

DOI  :  10.3390/ijms161226211

来源: mdpi

【 摘 要 】

Ocular pathologic angiogenesis is an important causative risk factor of blindness in retinopathy of prematurity, proliferative diabetic retinopathy, and neovascular macular degeneration. Guibi-tang (GBT) is a frequently used oriental herbal formula in East Asian countries, and is also called Qui-pi-tang in Chinese and Kihi-To in Japanese. In the present study, we investigated the preventive effect of GBT on retinal pathogenic neovascularization in a mouse model of oxygen-induced retinopathy (OIR). C57BL/6 mice were exposed to 75% hyperoxia for five days on postnatal day 7 (P7). The mice were then exposed to room air from P12 to P17 to induce ischemic proliferative retinopathy. GBT (50 or 100 mg/kg/day) was intraperitoneally administered daily for five days (from P12 to P16). On P17, Retinal neovascularization was measured on P17, and the expression levels of 55 angiogenesis-related factors were analyzed using protein arrays. GBT significantly decreased retinal pathogenic angiogenesis in OIR mice, and protein arrays revealed that GBT decreased PAI-1 protein expression levels. Quantitative real-time PCR revealed that GBT reduced vascular endothelial growth factor (VEGF), fibroblast growth factor 2 (FGF2), and plasminogen activator inhibitor 1 (PAI-1) mRNA levels in OIR mice. GBT promotes potent inhibitory activity for retinal neovascularization by decreasing VEGF, FGF2, and PAI-1 levels.

【 授权许可】

CC BY   
© 2015 by the authors; licensee MDPI, Basel, Switzerland.